BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29441961)

  • 21. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
    Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
    J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
    Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
    Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein.
    Vogler M; Dickens D; Dyer MJ; Owen A; Pirmohamed M; Cohen GM
    Biochem Biophys Res Commun; 2011 May; 408(2):344-9. PubMed ID: 21514278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
    Zhang S; Li G; Ma X; Wang Y; Liu G; Feng L; Zhao Y; Zhang G; Wu Y; Ye X; Qin B; Lu J
    Cell Signal; 2012 Sep; 24(9):1803-9. PubMed ID: 22609455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
    Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
    Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
    Pan R; Hogdal LJ; Benito JM; Bucci D; Han L; Borthakur G; Cortes J; DeAngelo DJ; Debose L; Mu H; Döhner H; Gaidzik VI; Galinsky I; Golfman LS; Haferlach T; Harutyunyan KG; Hu J; Leverson JD; Marcucci G; Müschen M; Newman R; Park E; Ruvolo PP; Ruvolo V; Ryan J; Schindela S; Zweidler-McKay P; Stone RM; Kantarjian H; Andreeff M; Konopleva M; Letai AG
    Cancer Discov; 2014 Mar; 4(3):362-75. PubMed ID: 24346116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance.
    van Oosterwijk JG; Herpers B; Meijer D; Briaire-de Bruijn IH; Cleton-Jansen AM; Gelderblom H; van de Water B; Bovée JV
    Ann Oncol; 2012 Jun; 23(6):1617-26. PubMed ID: 22112972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid regulation of the ABCB1 and ABCG2 multidrug transporters.
    Hegedüs C; Telbisz Á; Hegedűs T; Sarkadi B; Özvegy-Laczka C
    Adv Cancer Res; 2015; 125():97-137. PubMed ID: 25640268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
    Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
    Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1).
    Xu Y; Egido E; Li-Blatter X; Müller R; Merino G; Bernèche S; Seelig A
    Biochemistry; 2015 Oct; 54(40):6195-206. PubMed ID: 26381710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.
    Boesch M; Zeimet AG; Rumpold H; Gastl G; Sopper S; Wolf D
    Stem Cells Transl Med; 2015 Sep; 4(9):1028-32. PubMed ID: 26136502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
    Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
    Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.
    Neumanova Z; Cerveny L; Ceckova M; Staud F
    AIDS; 2014 Jan; 28(1):9-17. PubMed ID: 24413260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.